TABLE 2.

Cross-neutralizing activity against heterologous virus, determined by using plasma from antiretroviral-untreated subjects^a

Source of virus	Neutralizing antibody titer from plasma fromb:
	Virologic controller patient					Virologic noncontroller patient
	1009	1050	1056	1086	4006	1027	1028	1503
Patient groups and ID no.
Controllers
1009	68*	42	70	725*	50	433*	122*	41
1050	54	136*	83*	491*	76*	245*	167*	153*
1056	19	36	72	50	46	31	42	58
1086	35	27	26	73*	52	34	299*	55
4006	47	65*	58	104*	126*	68*	59	102*
Noncontrollers
1027	21	34	42	71*	42	246*	78*	69
1028	65*	88*	101*	300*	76*	270*	98*	95*
1503	48	91*	77	457*	75*	395*	128*	186*
Virus and lab strains
aMLV	20	20	27	20	23	20	20	26
JR-CSF	32	59	63	174	62	155	184	57
NL4-3	818	1,630	877	1,519	524	1,864	2,204	2,848

^aNeutralizing HIV antibody titers were measured in plasma derived from chronically infected, antiretroviral-untreated subjects meeting our study definition of virologic controllers or noncontrollers (patient identification [ID] numbers are given). These data reflect the average cross-neutralization titers determined by using plasma from two to four consecutive visits.

^bThe neutralizing antibody titer is defined as the reciprocal of the dilution of plasma that produces 50% inhibition of target cell infection. Values marked with an asterisk indicate neutralizing titers that are at least three times greater than those observed against the negative control virus (aMLV). Numbers in bold indicate that the neutralizing antibody titer was derived using plasma and virus from the same subject (autologous virus). Titers against laboratory strains (JR-CSF and NL4-3) and against aMLV are also shown.